Monday, November 29, 2021


6 days ago — FDA received case reports of TASS (Toxic Anterior Segment Syndrome) following intraocular administration of compounded drugs using moxifloxacin as a bulk ...

Tuesday, November 23, 2021


10 hours ago — the new rules, a non-resident compounding pharmacy must have an Ohio licensed pharmacist as the responsible person on its Ohio terminal distributor license

Sagent Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Levetiracetam Injection, USP Due to Lack of Sterility Assurance



Company Announcement Date:
FDA Publish Date:
Product Type:
Reason for Announcement:
Lack of sterility assurance
Company Name:
Sagent Pharmaceuticals, Inc.
Brand Name:
Product Description:
Levetiracetam Injection

Company Announcement

CHICAGO, IL – November 19, 2021 - Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of four lots of Levetiracetam Injection, USP, to the user level. The lack of container closure integrity, found in reserve sample vials may result in a non-sterile product.

Risk Statement: Intravenous administration of a product intended to be sterile that is not sterile could result in serious systemic infections which may be life threatening.  To date, Sagent has not received reports of any product complaints or adverse events associated with this issue.

Levetiracetam Injection, USP 500 mg per 5 mL, is used in the treatment of certain types of seizures and is packaged in a 5mL single-does vial. The Levetiracetam Injection, USP, label and affected lot numbers with Expiration Dates and NDC number can be found in the table below.  Product was distributed Nationwide from March to November  2021.



Expiration Date

NDC Number

Distribution Dates

 Levetiracetam Injection, USPB0G85VBJun-202225021-
May 2021 -
August 2021
B0K88VASep-2022March 2021 -
November 2021
B0K89VASep-2022August 2021 -
November 2021
B1G194AJun-2023October 2021 

Sagent Pharmaceuticals, Inc.  is notifying customers by fax, email, FedEx, and/or certified mail, which includes arrangements for return of all recalled product. Customers that have Levetiracetam Injection, USP 500mg per 5 mL, which is being recalled, have been instructed to examine their inventory immediately and to quarantine, discontinue distribution of, and return as directed the recalled lots of product. Customers who may have further distributed this product have been requested to identify their customers and notify them at once of this product recall. Healthcare/distributors/retailers that have product which is being recalled should stop using product and return the recalled product. The necessary form to document product information, as well as other information regarding this recall, is available at www.Sagentpharma.comExternal Link Disclaimer.

Consumers or healthcare workers with any questions regarding this recall can contact the customer call center (866) 625-1618 M-F, 8am-7pm CST. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company Contact Information

Customer Call Center
 (866) 625-1618

Product Photos

 "Nov. 2, 2021: Update – In October 2020, FDA was sued by seven compounding pharmacies in the U.S. District Court for the District of Columbia regarding the final standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products. In September 2021, the Court remanded the MOU to FDA to either certify that it will not have a significant economic effect on small businesses or prepare a regulatory flexibility analysis. FDA is evaluating the Court’s decision.

Before the Court’s decision, FDA extended the period before FDA intends to begin enforcing the statutory 5 percent limit on distribution of compounded human drug products out of the State in which they are compounded in States that do not sign the  final standard MOU, to October 27, 2022.

FDA plans to provide additional updates, as appropriate, with regard to the MOU."

quoted from

Monday, November 22, 2021


Court Enjoins California Company from Manufacturing and Distributing Adulterated Sterile Animal Drugs

A federal court enjoined a California company from distributing adulterated sterile animal drugs in violation of the Federal Food, Drug and Cosmetic Act (FDCA), the Department of Justice announced.

In a complaint filed on Oct. 27, 2020 in the Central District of California, the United States alleged that multiple inspections by the U.S. Food and Drug Administration (FDA) repeatedly showed that Med-Pharmex Inc. (MPX) manufactured and distributed animal drugs under conditions that fell short of the minimum regulatory requirements to ensure safety and quality, including a failure to maintain sterility. According to the complaint, the FDA issued a warning letter to MPX in 2017 regarding numerous deficiencies found at the company. The complaint further alleged that the company failed to adequately investigate reports regarding the death or illness of animals receiving certain MPX drugs, and failed to properly clean and disinfect areas used to manufacture sterile drugs, as required by the FDCA. MPX and company president Gerald P. Macedo agreed to settle the suit and to be bound by a consent decree of permanent injunction that resolves the case.

Read More Button

Thursday, November 18, 2021


3 days ago — Wedgewood Pharmacy, the largest compounding pharmacy in the U.S. devoted to animal health, has created a Veterinary Advisory Board comprising 11 ...

California State Board of Pharmacy Intends to Enter the Food and Drug Administration’s Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products November 17, 2021 — 




Tuesday, November 16, 2021


Investigations Newsletter: DOJ Files Complaint in AWP False ...

11 hours ago — (PCCA), a Houston-based company that sells pharmaceutical ingredients and other products and services to compounding pharmacies. The government alleges that


Non-Resident Pharmacy Compounding in Ohio

7 days ago — The compounding pharmacy's responsible person must be Ohio Licensed by 12/1/2021: A pharmacy licensed as a non-resident pharmacy that is engaged.

Wednesday, November 10, 2021


7 days ago — Because compounding from these substances presents risks to patients, ... pharmacist or physician, or an outsourcing facility, might compound a drug product

Kaleo settles U.S. probe over pricy overdose treatment for $12.7 million By Nate Raymond 


The last drugstore: Rural America is losing its pharmacies

11 hours ago — More than 1000 independent pharmacies in rural America have closed since 2003, leaving 41 million people stuck without easy access to drug stores.


What Fraud on the FDA Really Looks Like - Drug & Device Law

12 hours ago — Pharmacy compounding has a long history and is an entirely legitimate practice. Ordinarily the states regulate the practice of pharmacy, but since compounding 

U.S. v. Carter, 15 F.4th 26 (1st Cir. 2021), where the government successfully prosecuted a claim for fraud on the FDA, involving the concealment of unlicensed pharmaceutical manufacturing in guise of “pharmacy compounding. 

Oklahoma Supreme Court Throws Out $465 Million Opioid Ruling Against J.&J. The 5-1 decision is a setback for those who are fighting to hold big drug makers accountable for the opioid epidemic. 

If you take this pain medicine, there’s an FDA recall so stop and call your doctor Chris Smith 8 hrs ago

Tuesday, November 9, 2021


Why Regulatory, Compliance Lawyers Should Watch This ...

9 hours ago — The defendant, Professional Compounding Centers of America Inc., ... the amount to reimburse pharmacies for the compound prescription claims they submit.


Texas Pharma Company Inflated Prices Over 400 Times ...

13 hours ago — 8, the DOJ filed the complaint under the False Claims Act against Professional Compounding Centers of America Inc. (PCCA), for blowing up Average Wholesale ...

Prosecutors say Houston-based Professional Compounding Centers of America Inc knowingly reported inflated average wholesale prices for its ingredients.


Justice Department accuses drug company of inflating prices

1 day ago — Prosecutors say Houston-based Professional Compounding Centers of America Inc knowingly reported inflated average wholesale prices for its ingredients.

PCCA Response to DOJ Filing PCCA (GLOBE NEWSWIRE) Nov 8, 2021 Updated Nov 8, 2021 


FDA reiterates support for semi-distributed tracing model ...

6 days ago — The US Food and Drug Administration (FDA) recommends that trading partners ... medical gas, homeopathic drugs and compounded drugs are not subject to the ...


Texas Pharmacy Today is a weekly e-newsletter

5 days ago — "Texas already has solid rules for non-sterile compounding in current ... care by limiting the ability for such pharmacists to compound needed medications.


Infusion Options, Inc. - 612459 - 08/26/2021 | FDA

21 hours ago — Compounding Pharmacy/Adulterated Drug Products. ... For a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug ...